Biocon | Target: Rs 823 | Key developments during the quarter gone by include the approval of Fulphila (Pegfilgrastim) Biosimilar, co-developed by Biocon and Mylan for launch in US markets. We expect the company to grow at a CAGR of around 29% over the next two years, which should also result in an improvement in its profit margins.